CLZ-2002

Phase 1Small molecule

UUnknown Sponsor

CLZ-2002 is one of 10 small molecule programs targeting Tooth Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tooth DiseaseActive, not recruiting

Tooth DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Tooth Disease

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Tylenol

Methylthioninium Chloride

PProvepharm SAS

Approved

—4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Advil

Circadin

NNeurim Pharmaceuticals Ltd.

Mexitil

1 8

Ozone

TTanta University

Phase 2

—9

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

CLZ-2002

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tooth Disease1 trial

The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.

Completed·UUnknown Sponsor·Phase 1·NCT05947578·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CLZ-2002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLZ-2002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLZ-2002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUnknown Sponsor

CLZ-2002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tooth Disease1 trial

References

Drug Info

Quick Facts

Related News